Results 21 to 30 of about 103,481 (331)

Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]

, 1997
Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J., Chaudhuri, K.R., Ellis, C, Leigh, P.N., Lemmens, Gilbert, Parkes, J.D., Pye, I.F.   +6 more
core   +2 more sources

Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations [PDF]

, 2014
In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin neurons possess the enzymatic machinery able to convert exogenous l-DOPA
CARTA, MANOLO, TRONCI, ELISABETTA
core   +1 more source

Clinical Aspects and Management of Levodopa-Induced Dyskinesia

Parkinson's Disease, 2012
In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias.
Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabresi   +7 more
doaj   +1 more source

Orexin-Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine [PDF]

, 2015
Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced cocaine-seeking behavior.
Aguinaga, David, Cai, Ning-Sheng, Canela, Enric I, Casadó, Vicent, Cortés, Antonio, Ferré, Sergi, Hausch, Felix, Howell, Lesley A., Lluís, Carme, Mallol, Josefa, McCormick, Peter J., McDowell, Kimberly, Moreno, Estefanía, Moreno-Delgado, David, Navarro, Gemma, Quiroz, César, Rea, William, Sierakowiak, Adam   +17 more
core   +1 more source

Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. [PDF]

, 2017
BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD).
de Boer, L, Edwards, MJ, Haggard, P, Morgante, F, Ricciardi, L, Sorbera, C, Stenner, M-P   +6 more
core   +2 more sources

Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors [PDF]

, 2015
Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces numerous undesirable effects, including memory impairments, anxiety, and dependence.
A Busquets-Garcia, A Castañé, A Kern, A Manglik, A Pazos, A Pertovaara, A Zimmer, AC Magalhaes, AJ Venkatakrishnan, AL Bodor, Antoni Pastor, AR Best, Arnau Cordomí, BB Gorzalka, C Bombardi, C Castellano, C Ferrada, C Sanchis-Segura, Carmen Lluís, CP Vandermaelen, E Aso, E Fiorica-Howells, E Moreno, E Moreno, E Moreno, E Palazzo, E Puighermanal, E Puighermanal, E Valjent, Enric I. Canela, Eric J. Nestler, Estefanía Moreno, ET Weber, F Berrendero, F Rodríguez de Fonseca, F Simonin, F Steindel, FA Moreira, G Di Chiara, G Mengod, G Paxinos, G Porras, G Soria, Gemma Navarro, GM Thomas, HY Meltzer, J De Almeida, J González-Maeso, J González-Maeso, JC Parrish, JF Cheer, JF López-Giménez, JF López-Giménez, JJ Rodriguez, JM Franklin, JM Walker, JR Clapper, K Baba, K Mackie, K Monory, K Tsou, K Tsou, KA Gleason, L a. H Miner, L Callén, L Lanfumey, Laurence Lanfumey, Leonardo Pardo, Lesley A. Howell, LJ Sim-Selley, LP Martin, LTO Lee, M Bouvier, M Fribourg, M Lüttgen, M Schneider, M-M Mocanu, MJ Orejarena, N Kabli, NA Darmani, NB Eddy, NV Weisstaub, O Söderberg, P Pacher, P Rivera, Paola Gasperini, Patricia Robledo, Peter J. McCormick, R Franco, R Maldonado, R Mechoulam, R Mongeau, R Nygaard, R Schroder, Rafael de La Torre, Rafael Maldonado, RL Jakab, S Ferre, S Ferré, S Ferré, S González, S Haj-Dahmane, S Mato, S Pellow, SGF Rasmussen, SGF Rasmussen, SM Eggan, T Issad, T-W Chen, V Mendizábal, X Guitart, Xavier Viñals, Y-C Chiang   +112 more
core   +5 more sources

Conditioned place preference and locomotor activity in response to methylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors [PDF]

, 2010
Methylphenidate (MP) and amphetamine (AMPH) are the most frequently prescribed medications for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Bermeo, C., Grandy, David K., Rubinstein, Marcelo, Suchland, K. L., Thanos, P. K., Volkow, N. D., Wang, G. J.   +6 more
core   +1 more source

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma

Journal of Investigative Medicine High Impact Case Reports, 2021
Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine.
Lakshmi P. Menon MD, Wedad Rahman MD
doaj   +1 more source

The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]

, 2016
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea, Diaz, Graciela Susana, Recouvreux, Maria Victoria, Rifkin, Daniel B.   +3 more
core   +2 more sources

A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson's disease.

PLoS ONE, 2019
Schizophrenia and Parkinson's disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists ...
Ana Martínez, Ilich A Ibarra, Rubicelia Vargas   +2 more
doaj   +1 more source